Khader attends workshop conference on health in Thailand

Kalaburagi, Feb 16: Fourteen years of life in jail has not deterred Subhash Patil from fulfilling his dream of becoming a doctor.

The 40-year-old man from Afzalpura in Karnataka's Kalaburagi was put behind bars in a murder case while doing MBBS in 1997.

Speaking to media, Patil said, "I joined MBBS in 1997. But, I was jailed in a murder case in 2002. I worked at the jail's OPD and was released in 2016 for good conduct. I completed my MBBS in 2019."

Earlier this month, Patil completed a one-year mandatory internship for getting the MBBS course degree.

Police arrested Patil in 2002 in a murder case when he was in his third year of MBBS course. A court sentenced him to life imprisonment in 2006.

He was put behind bars but he did not give up his childhood dream of becoming a doctor.

In 2016, police released Patil on Independence day for his good conduct.

Mangaluru, Jul 2: A frontline covid-19 warrior who was working in the Wenlock Covid hospital in the city has been tested positive for the coronavirus. 

Sources said that he was a pathologist working in covid testing laboratory of the Wenlock Covid hospital.

A few days ago, a senior health official had tested positive for the covid-19.

Dakshina Kannada has so far recorded deaths of 18 covid-19 patients. A total of 14,137 samples have been tested, out of which 13,040 have turned out negative, and 833 positive, including 10 persons from other districts. 372 cases are currently active.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.